What is survival rate for AML after transplant?

If an allogeneic stem cell transplant is done during first remission, the 5-year disease-free survival rate is 30%–50%. If there has been no recurrence at 2 years after the stem cell transplant, the person has about an 80% chance of staying in complete remission for a long period of time.

Can AML come back after transplant?

Disease recurrence is a devastating event after allogeneic hematopoietic stem cell transplantation as treatment for acute myeloid leukemia (AML). Median time to relapse is approximately 4 months and the majority of relapses occur within 2 years after transplant. The prognosis is usually poor.

Does bone marrow transplant cure AML?

Bone-marrow transplantation from an HLA-identical sibling is effective in eradicating leukaemia in most patients with acute myelogenous leukaemia (AML) in first remission. The efficacy is widely assumed to be related to the high doses of drugs and radiation administered before transplantation.

How successful is a bone marrow transplant for AML?

Allogeneic transplantation using stem cells or bone marrow from a tissue-matched brother or sister or unrelated donor produces cure rates of approximately 50 percent to 60 percent in patients with intermediate-risk AML.

How is acute myeloid leukemia ( AML ) treated?

Acute myeloid leukemia (AML) is a phenotypically and prognostically heterogeneous hematopoietic stem cell disease that may be cured in eligible patients with intensive chemotherapy and/or allogeneic stem cell transplantation (allo-SCT).

What are the long term effects of AML treatment?

Long term side effects of treatment for acute myeloid leukaemia (AML) 1 Possible side effects. You might have one or more of these effects. 2 Problems specific to children. As well as the possible side effects listed above,… 3 Coping with late effects. It can be difficult to cope with problems that develop after treatment.

Can a person with acute myeloid leukemia get a stem cell transplant?

Some may still be able to get a non-myeloablative transplant (also known as a mini-transplant or reduced-intensity transplant), where they get lower doses of chemo and radiation that don’t completely destroy the cells in their bone marrow. They then get the allogeneic (donor) stem cells.

Can a non myeloablative transplant work with less toxicity?

A non-myeloablative transplant can still sometimes work with much less toxicity. In fact, a patient can get the transplant as an outpatient. The major complication is graft-versus-host disease. Many doctors still consider this an experimental procedure for AML, and it is being studied to determine how useful it may be.